ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors. Its aim is to create the suppressor tRNA-nanoparticle therapeutics for the correction of genetic mutations. The company focuses on the treatment of cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD).